Clinical Trials Logo

Advanced Malignant Tumor clinical trials

View clinical trials related to Advanced Malignant Tumor.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06022250 Not yet recruiting - Clinical trials for Advanced Malignant Tumor

The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor

Start date: September 15, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase I open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK),Pharmacodynamic characteristics, immunogenicity and antitumor activity of JS207 in patients with advanced malignant tumor. The Recommended dose for phase II trial (RP2D) will be determined based on the safety, tolerability, pharmacokinetics.

NCT ID: NCT05318833 Not yet recruiting - Clinical trials for Advanced Malignant Tumor

A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors

Start date: April 15, 2022
Phase: Phase 1
Study type: Interventional

This study is a multicenter, open phase I clinical study of dose escalation and dose extension of HRS7415 in subjects with advanced malignant tumors. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS7415 tablets.

NCT ID: NCT05015309 Not yet recruiting - Clinical trials for Advanced Malignant Tumor

A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor

Start date: September 2021
Phase: Phase 1
Study type: Interventional

The primary objective is to determine the safety and tolerability of SH3765 in subjects with advanced malignant tumor by determining the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). The second objective is to evaluate the PK profile and preliminary efficacy of SH3765 in subjects with advanced malignant tumor.